{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "HAEMOGLOBINOPATHY SCREENING IN PREGNANCY"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "08041"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "7.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Obstetricians, Midwives"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "11 November 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "10 November 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "NHS Sickle Cell and Thalassaemia Screening Programme Standards 2017 Intrapartum NICE Guidelines RCOG guideline"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "11,12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Women's and Children's"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Emma Neate, Antenatal and Newborn Screening Co-ordinator Miss Kausar, Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Maternity and Gynaecology Practice Steering Group"
                    },
                    {
                        "text": "08 October 2020"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss Rao, Lead Consultant"
                    },
                    {
                        "text": "08 October 2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "03 November 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from the Joint Document Management Group)"
                    },
                    {
                        "text": "November 2020"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612 Trust Intranet \u2612 Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Anita Rao"
                    },
                    {
                        "text": "Clinical Director for Women and Children's Division"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Vidya Thakur"
                    },
                    {
                        "text": "Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Dr Hassan"
                    },
                    {
                        "text": "Consultant Paediatrician"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Alison Cuthbertson"
                    },
                    {
                        "text": "Associate Director of Midwifery/ Nursing"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Lead Midwife Acute Inpatient Services"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Chris Berner"
                    },
                    {
                        "text": "Lead Midwife Clinical Governance"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Lead Midwife Community Services"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Sarah Iskander"
                    },
                    {
                        "text": "Antenatal Clinic Midwife"
                    },
                    {
                        "text": "16 October 2018"
                    },
                    {
                        "text": "Reginald Caples"
                    },
                    {
                        "text": "Senior BMS for Haematology"
                    },
                    {
                        "text": "06 August 2020"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "(Refer to the main body of the text) 04071 Standard Infection Prevention 04072 Hand Hygiene 06036 Guideline for Maternity Record Keeping including Documentation in Handheld Records 08011 Iron deficiency Anaemia in pregnancy 09113 Guideline for calling paediatric staff and obtaining paediatric referral 09062 Maternity Care 04181 Blood Transfusion Policy 06031 Receiving and Acting on Test Results in Maternity by both Hospital and Community"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Nina Smethurst & Yvonne Roder"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "July 2006"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Dr Gupta"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "April 2008"
                    },
                    {
                        "text": "3.1"
                    },
                    {
                        "text": "Sarah Moon & Kathy Bird"
                    },
                    {
                        "text": "Additional appendix A, point 13 and 14 update"
                    },
                    {
                        "text": "June 2010"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "February 2012"
                    },
                    {
                        "text": "4.1"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": "Addition to appendix B; Point 5.0"
                    },
                    {
                        "text": "September 2012"
                    },
                    {
                        "text": "5.0"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "3 August 2015"
                    },
                    {
                        "text": "6.0"
                    },
                    {
                        "text": "Emma Neate & Sameena Kausar"
                    },
                    {
                        "text": "Full review"
                    },
                    {
                        "text": "31 October 2018"
                    },
                    {
                        "text": "7.0"
                    },
                    {
                        "text": "Emma Neate"
                    },
                    {
                        "text": "Full review: NHS Sickle Cell and Thalassaemia Screening Programme Standards 2017 Addition of new point 3.0, 4.0 and 10.0, and subsequent renumbering and clarification to point 2.0,11.0, 22.0 and 23.0"
                    },
                    {
                        "text": "11 November 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose ...............................................................................\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u20265"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality Impact Assessment ..................................................................................... 5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Rationale and Recommendations ............................................................................. 5  Roles and Responsibilities \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u20266"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Background ................................................................................................................. 6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Screening .................................................................................................................... 7"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Women who Decline Screening ................................................................................. 9"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Women who miscarry or teminate their pregnancy ............................................... 10"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Late and unbooked women ...................................................................................... 10 10 Failsafe for Screening .............................................................................................. 10  Reporting Incidents\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202610  Results\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202611 High Risk Couples\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...13 Sickle Cell Disease related Complications During Pregnancy\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...15 Sickle Cell disease in Labour\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202616 Indications for Blood Transfusion in Sickle Cell Disease during Pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "and the Postpartum period\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202617  Management of Sickle Cell Crisis\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.17 Acute Chest Syndrome\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202619 Management of Thalassaemia in Pregnancy\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.20 Staff and Training\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..24 Infection Prevention\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.....24 Audit and Monitoring\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026..25"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "Approval and Implementation\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026\u2026\u2026\u2026.....26  References\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202626 Appendix A: Preliminary Equality Assessment \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...27 Appendix B: Letter to Women regarding results\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..28 Appendix C: Haemoglobinopathy Alert Form\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...29 Appendix D: Antenatal and Newborn Screening Haemoglobinopathy Screening SOP ..\u2026\u2026.30"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "The purpose of this guideline is to aid medical and midwifery staff in management of patients with haemoglobinopathies during their pregnancy and labour. This is in keeping with the increase in number of pregnant women in the U.K. who may be carriers or suffer from the disease."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality impact assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Mid and South Essex NHS Foundation Trust is committed to the provision of a  service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Rationale for recommendations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "This guideline is written with reference to the NHS Sickle Cell and Thalassaemia Screening Programme Standards 2017"
            }
        },
        {
            "type": "table",
            "sequence_num": 25,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Screening Standards"
                    },
                    {
                        "text": "Definition"
                    },
                    {
                        "text": "Evidence in Guideline of Standard"
                    },
                    {
                        "text": "Standard 1"
                    },
                    {
                        "text": "To provide assurance that screening is offered to all eligible women and each woman accepting screening has a screening result. Timely information on screening coverage is important to identify trends and monitor the effectiveness of service improvements. Coverage is a measure of the delivery of screening to an eligible population. Low coverage might indicate that: not all eligible women were offered screening those offered screening are not accepting the test those accepting the test are not being tested"
                    },
                    {
                        "text": "See section 4.2"
                    },
                    {
                        "text": "Standard 2"
                    },
                    {
                        "text": "To identify carrier and affected women by 10 weeks + 0 days of pregnancy to allow the baby's biological father to be offered testing and to offer of PND to women at risk of having an affected infant by 12 weeks + 0 days of pregnancy"
                    },
                    {
                        "text": "See section 4.7"
                    },
                    {
                        "text": "Standard 3"
                    },
                    {
                        "text": "To interpret screening results in high prevalence areas and to identify women at higher risk to be offered further testing in low prevalence areas A completed FOQ must use the national template (paper or electronic format), and must include: at least one box for the mother or options for \u2018declined to answer' or \u2018don't know' selected at least one box for the father or options for \u2018declined to answer' or \u2018don't"
                    },
                    {
                        "text": "See section 4.17"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 26,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "know' selected gestational age or gestational age \u2018not known' recorded"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Standard 5"
                    },
                    {
                        "text": "There is a known association between gestation at screening offer and uptake of PND, with the early offer of screening being associated with greater uptake of PND. The majority of PND currently takes place after 12 weeks + 6 days. Approximately half of women at risk of having an affected infant decline PND; gestational age at time of decline is not known"
                    },
                    {
                        "text": "See section 10.0"
                    },
                    {
                        "text": "Standard 6"
                    },
                    {
                        "text": "Timely intervention and choice in procedure for those who accept PND Proportion of PND tests performed by 12 weeks + 6 days gestation"
                    },
                    {
                        "text": "See section 10.4"
                    },
                    {
                        "text": "Standard 7"
                    },
                    {
                        "text": "To provide information about living with and supporting an affected child and if chosen, to ensure timely referral for termination of pregnancy: Maximise informed choice Proportion of results received within 5 working days of PND procedure"
                    },
                    {
                        "text": "See section 10.5"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Specialist Nurse for Guidelines and Audit is responsible for ensuring clinical policies, guidelines and SOPs, are evidence-based and developed in line with national guideline and following appropriate consultation."
            }
        },
        {
            "type": "image",
            "sequence_num": 29,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The Antenatal and Newborn Screening Co-ordinator has overall responsibility for the screening programme service needs and care provided."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The Failsafe Officer is responsible for ensuring all women have results for all screening tests."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "The Maternity Phlebotomist is responsible for taking required screening samples."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "The Screening team is responsible for contacting, counselling and arranging follow up care where required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The clinical director is responsible for the implementation of this guideline within the directorate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The Head of Midwifery, maternity matrons and maternity managers are  responsible for ensuring maternity staff are aware of the guideline and implement it."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "The Obstetric Clinical Lead Consultant and Labour Ward Lead Consultant are responsible for ensuring the implementation of this guideline within the clinical setting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "All maternity staff are responsible for ensuring they are familiar with this guideline in relation to their practice and have the appropriate skills to implement this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Sickle Cell and Thalassaemia, otherwise known as Haemoglobinopathies, are autosomal, recessive inherited conditions that affect haemoglobin structure or synthesis. Approximately 1000 haemoglobin gene variants have been identified worldwide (BMJ, 2010)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "Inheritance of an altered gene variant from both parents results in an affected baby and inheritance of only one altered gene variant results in a healthy carrier."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 12.0,
                "text": "SCD is the most common inherited condition worldwide. In the UK, it is estimated that there are  000\u201315 000 affected individuals and over 300 infants born with SCD in the UK each year who are diagnosed as part of the neonatal screening programme. There are approximately 100\u2013200 pregnancies in women with SCD per year in the UK (RCOG Green top GL)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "The NHS Sickle Cell and Thalassaemia Antenatal and Newborn Screening Programme screens for:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "Genetic carriers for sickle cell, thalassaemia and other haemoglobin disorders;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "Sickle cell disease;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Thalassaemia;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobin disorders."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "It offers screening to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "All pregnant women;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "Fathers-to-be, where antenatal screening shows the mother is a genetic carrier;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "All newborn babies, as part of the Newborn Blood Spot Screening Programme."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Objectives and outcomes of the SCT antenatal programme:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "To offer timely antenatal sickle cell and thalassaemia screening to all women (and couples), to facilitate informed decision-making;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "For those women accepting prenatal diagnosis (PND), 50% of prenatal diagnoses to be performed before 12 weeks + 6 days."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "Objectives and outcomes of the SCT newborn programme:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "To identify babies born with conditions where early intervention is likely to be beneficial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "To achieve the lowest possible childhood death rate and to minimise childhood morbidity from sickle cell diseases."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": "The aim of offering screening in pregnancy is to identify couples who are at risk of having an affected child, provide them with information and support to ensure informed choices are made during pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 6.6,
                "text": "It is important that screening is offered early to ensure the results of the screening test and any referrals for Prenatal Diagnosis Testing (PND) are available early for women/couples so they are able to make timely informed choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 10.0,
                "text": "Universal screening for sickle cell, thalassemia and any unusual haemoglobin variant should be offered to all women as early as possible in pregnancy, ideally by  weeks gestation. Screening should be offered at whatever gestation the woman first presents as this may still be of clinical benefit. Testing of the father of the baby will be requested if the woman is confirmed as a carrier."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 6.8,
                "text": "In low prevalence areas; such as MSE NHS FoundationTrust, Broomfield Hospital, it is based on red cell indices from the booking full blood count (FBC) and ethnic origin, with history of Haemoglobinopathy in the patient, her family or partner, also his family history."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 6.9,
                "text": "All pregnant women should be provided with written information \u2018Screening tests for you and your baby' prior to their booking appointment. This is available in English and 12 other languages, via www.gov.uk/government/publications/screening-tests-for-you-and-your- baby-description-in-brief"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "For those women who do not have English as a first language, they must be offered interpreting services to help them make an informed choice about screening. It is not acceptable to use a friend or family member to translate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "prefix": 6.11,
                "text": "The health professional offering the screening test must ensure the woman understands the test, has given her consent for antenatal screening and is aware of the choices that will follow if the test is positive."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 6.12,
                "text": "When offering screening for sickle cell and thalassaemia, healthcare professionals must:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "Give verbal and written information about the screening test, using the booklet Screening tests for you and your baby"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "Offer the woman an opportunity to discuss the screening test and her decision"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "Offer resources to address any specific needs that the woman has such as literacy, visual impairment, language needs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "Be aware of, and sensitive to, the woman's values and beliefs and support the woman to make decisions which are right for her"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "Record consent or non-consent for screening in the woman's maternity notes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "Communicate non-consent for screening to appropriate professionals, including laboratory staff"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "Establish whether or not couples are already aware of their screening status. Known \u2018at risk' couples should be fast tracked for timely PND to the screening team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "prefix": 6.13,
                "text": "Women and the baby's biological father (where relevant) must be offered screening for sickle cell and thalassaemia in every pregnancy, irrespective of their previous result. However, it is only necessary to offer screening once in the same pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "prefix": 6.14,
                "text": "During booking for antenatal care it is important for healthcare professionals to gather information relevant to the sickle cell and thalassemia screening programme. This includes questions about:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "Adoption or a possible lack of awareness of family ancestry on the part of either parent;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "Fertility treatment:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "Current regular blood transfusions or history of blood transfusion (why, when, where and frequency);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "History of bone marrow or stem cell transplant (why, where and when);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "History of haemoglobin disorders or other inherited conditions (for either parent or in either of their families)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "text": "When a woman discloses that she or the father of the baby are a known carrier for Sickle cell or Thalassemia or that they answer yes to any of the above; the screening team should be informed as soon as possible, to ensure early care and further screening."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "prefix": 6.15,
                "text": "All blood tests should be offered and undertaken at booking or within a week to ensure early identification of screening issues and the need for further screening and investigations as early as possible in pregnancy. (Refer to \u2018Guideline for Maternity Care; register number 09062)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "prefix": 6.16,
                "text": "Although people from any population can have these conditions, individuals from some geographical areas of the world are more likely to be a genetic carrier based on their ancestry. The aim of the FOQ is to identify the population groups at highest risk of sickle cell, thalassaemia and other haemoglobin variants."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobinopathy screening in pregnancy/08041/7.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "prefix": 6.17,
                "text": "Completion of the FOQ information is the responsibility of the healthcare professional booking the woman for antenatal care. Details are required:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "For both the baby's biological mother and father in both high and low prevalence areas;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "To be completed in every pregnancy and sent with the blood sample to the laboratory, or be accessible to the laboratory team if using an electronic system;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "For all ancestry, as far back as the individual can remember (at least 2 generations, but more if possible \u2013 this is particularly important for individuals with a mixed/multiple ethnic background)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Women who decline screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "When women decline screening tests the Midwife who offered the initial screen should inform them they will be contacted by a Screening Midwife to discuss their choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "7.1.1 Midwives need to inform the Screening office of declined screening."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "7.1.2 Women should be contacted by the Screening team as soon as possible and ideally before 20 weeks to discuss their decision to decline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "7.1.3 Reoffer the screening test and arrange testing and follow up the results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "7.1.4 The onus of the reoffer is to facilitate an informed choice and not to coerce women to accept."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Women who miscarry or terminate their pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "prefix": 8.1,
                "text": "Women who miscarry or terminate their pregnancy should receive their results. This will be done by The Screening Team and appropriate follow up appointments made if required. If results are low risk (negative) a letter will be sent to women informing them of their results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Late and unbooked women"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Late and unbooked women should be offered screening at the first possible opportunity. This may occur when they present in labour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "prefix": 9.2,
                "text": "In Utero transfers should ideally have copies of all antenatal screening blood results on transfer."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "prefix": 9.3,
                "text": "The receiving practitioner should make attempts to obtain these from the booking hospital, rescreening should be offered and the blood requested as urgent and results should be made available within 24 hours of the sample being taken by the laboratory."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Failsafe for screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Maternity Phlebotomist will review all women on the daily scan list for st trimester scans, they review all the screening results and check for completion of screening \u2013 these results are checked by a Antenatal Clinic or Screening Midwife, if any results are missing; these bloods will be taken with consent after the scan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "The Failsafe Officer will carry out a failsafe check following the woman's st trimester scan to ensure all screening results are available and to highlight any that are abnormal results to the screening midwives; this acts as a failsafe for abnormal results also. If any results are found to be missing, the following steps are followed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "Screening team will send one letter to the woman regarding the need to have bloods taken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Reporting incidents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Any incidents related to the screening pathway / programme need to be datixed via the Trust's incident reporting system, the Screening Coordinator / Deputy will review the Datix and if the incident meets the Antenatal and Newborn Screening Incident Criteria then an alert is sent by the Screening Team or Governance team to Public Health England (See Women's and Children's Division Clinical Governance Structure Policy 05098, 2019, Appendix B)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "prefix": 12.1,
                "text": "Negative results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "text": "If results are normal - No abnormality detected or Hb AA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "text": "The midwife should document the results in the woman's healthcare records at the 16-18 week visit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "Approximately 97% of women screened will have this result. No testing of the biological father is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "text": "Non-significant carrier"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "Not clinically significant and there is no risk of the baby inheriting a major haemoglobin disorder. No testing of the biological father is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "prefix": 12.2,
                "text": "Positive results \u2013 carrier result or affective result"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "Important to note women who are aware of their results may be familiar with the term \u2018Trait' or \u2018Trace'."
            }
        },
        {
            "type": "table",
            "sequence_num": 116,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Significant carrier"
                    },
                    {
                        "text": "This is clinically significant and the baby may be at risk of inheriting a major haemoglobin disorder if both parents are carriers. Around 2.5% or 1 in 40 pregnant women will be identified as carriers. Testing of the biological father is required."
                    },
                    {
                        "text": "Benign haemoglobin disorder"
                    },
                    {
                        "text": "This is, for example, Hb CC, Hb DD or Hb EE. The woman must be referred for a haematology consultation but often no special care during pregnancy is necessary. Screening of the biological father is required, and the baby may be at higher risk (50% chance) of inheriting a haemoglobin disorder if the father is a carrier of a significant haemoglobinopathy."
                    },
                    {
                        "text": "Clinically significant disorder"
                    },
                    {
                        "text": "This includes sickle cell disease, for example Hb SC, or thalassaemia condition. Most of these women are aware of their condition but on occasion this may be identified for the first time during antenatal screening. Urgent referral to hematology and consultant obstetric teams is needed. Joint medical and obstetric care and close monitoring throughout the pregnancy is necessary, and women should be booked for a hospital delivery. Testing of the baby's biological father is required. There is a higher risk (50% chance) of the baby inheriting a haemoglobin disorder if the biological father is a carrier of a significant haemoglobinopathy"
                    },
                    {
                        "text": "Inconclusive result"
                    },
                    {
                        "text": "Further testing of the woman may be required depending on the variant suspected. For these couples, the result should be explained to the woman and testing should be offered for the baby's biological father. If the baby's biological father does not have a haemoglobinopathy there is no risk of the baby inheriting a major haemoglobin disorder."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 117,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "There may be no further maternal testing required (this is locally determined). However, if there is no further testing of the woman she will remain unaware of her specific carrier status and the risks for a future pregnancy if she changes partners. If the baby's biological father does have a haemoglobinopathy, then further maternal testing may be required for an accurate assessment of the fetal risk of inheriting a significant haemoglobin condition, and the couples need to be followed up appropriately."
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "prefix": 12.3,
                "text": "If the result shows a haemoglobin gene variant, the results are sent to the Screening Team in Antenatal Clinic via the generic screening email: antenataland.newbornscreening@nhs.net  A receive receipt is sent back to acknowledge the sample."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "prefix": 12.4,
                "text": "Women who have inconclusive, carrier or affected results must be offered an opportunity to receive the result in a face to face counselling session with the screening team, in combination with the provision of written notification of the results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 12.5,
                "text": "The Screening team will contact the woman within 2 working days to arrange father of the baby screening (should be discussed with the woman as father of the baby (FOB) screening to ensure correct screening), for all patients identified as carriers. Rescreening should be offered for every pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 12.6,
                "text": "During the consultation information is given both verbally and written format. Haemoglobinopathy leaflets produced by the National Screening Committee will be offered to the women."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "prefix": 12.7,
                "text": "The father of the baby should be offered advice, support and screening without delay, along with the \u2018Tests for Dads' leaflet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "prefix": 12.8,
                "text": "Ideally, screening should take place early in pregnancy to allow for FOB screening, the offer of pre-natal diagnosis and the action of surgical termination, if requested."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "prefix": 12.9,
                "text": "The screening team will document FOB name and date of birth and review the results within 3-5 working days, the woman will then be contacted and informed of the results; this will also be followed up in writing a copy sent to the GP and Community Midwifery team (Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "Women are entered onto the Haemoglobinopathy Database for tracking and audit purposes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "High risk couples"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "If a woman and the father of the baby are both screened and found to be carriers of haemoglobinopathy variant, options are discussed during the consultation with the Specialist Midwife in Haemoglobinopathy or one of The Screening Team Midwives. Discussion will include the risks to the baby, management, long term health outcomes if known and the option of Prenatal Diagnosis Testing. The offer of further support/discussion with the Sickle Cell and Thalassaemia Specialist Nurses can be given arranged. They can be contacted at:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 13.2,
                "text": "The Antenatal Team will refer the patient to the haemoglobinopathy specialist nurse,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "Essex Sickle Cell and Thalassaemia Service Mayflower Community Hospital"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "text": "Blunts Wall Road"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "Billericay"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "text": "Essex"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "text": "CM12 9SA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "0300 300 1521 www.nelft.nhs.uk/services-bsbwtk-sickle-cell-thalassaemia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "prefix": 13.3,
                "text": "If the couples decide to have Prenatal Diagnosis (PND), this can be arranged by contacting UCLH Haemoglobinopathy centre \u2013 Mary Petrou on 0203 4479458."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "prefix": 13.4,
                "text": "An early scan will be arranged at MSE Broomfield Hospital to confirm dates PND can be performed from 11+2 weeks gestation. Women should be made aware the results will be available 10 \u2013 14 working days following the procedure."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 13.5,
                "text": "If PND performed and results confirm the baby has a major haemoglobinopathy, the couple will be invited back for a face to face consultation so that the results can be given. Discussion around the future plan for the pregnancy will determine the course of action. If the woman/couple decision is made to terminate the pregnancy this can be arranged by the screening team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "prefix": 13.6,
                "text": "If the decision is made to continue with the pregnancy support will be given by the Screening Midwife and the Community Sickle Cell and Thalassaemia Specialist Nurses; notification to the team via a Haemoglobinopathy Alert from (Appendix B). A copy of the result will be communicated to the Women, GP and Health Visitor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "prefix": 13.7,
                "text": "Please be aware that iron deficiency can co-exist with Haemoglobinopathy and this will need treatment. (Refer to the guideline for \u2018Iron deficiency anaemia in pregnancy'; register number 0801)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 1,
                "prefix": 13.8,
                "text": "Care in labour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "text": "13.8.1 If the woman is a carrier no specific care is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 1,
                "text": "13.8.2 Please note cord blood analysis is not required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 1,
                "prefix": 13.9,
                "text": "Postnatal Care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "13.9.1 If the woman is a carrier no additional care is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "text": "13.9.2 When performing the bloodspot screening (NBBS) for babies born to women who have been identified as being a carrier of Sickle Cell / Thalassaemia, the clinician performing the NBBS should document in the additional information box on the bloodspot card that mother is a carrier and if Father of the baby screening was performed the results of the screening for him . this information will assist the laboratory in screening the baby and ensuring appropriate care pathway for the baby."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "13.9.3 The Newborn Blood Spot Screening Programme will be performed at the appropriate time. If the result shows the baby is a carrier or inherited a Haemoglobinopathy disorder the parents will be informed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Sickle cell disease (affected women) related complications during pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Patients with Sickle Cell Disease (SCD) should be seen pre-conceptually by a sickle specialist to receive information about how SCD affects pregnancy and how pregnancy affects sickle cell disease, and how to improve outcomes for mother and baby."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "Preconceptually :"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "prefix": 14.2,
                "text": "Patients with SCD must be alerted as to the disease related complications. SCD is associated with both maternal and fetal complications:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "Fetal risks: Premature labour, Spontaneous miscarriage, fetal growth restriction."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "prefix": 14.3,
                "text": "Maternal risks: Antenatal hospitalisation, increased incidence of painful crises during pregnancy, infection, thromboembolic events, antepartum haemorrhage, pre-eclampsia and pregnancy-induced hypertension, delivery by caesarean section and postpartum infection."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "prefix": 14.4,
                "text": "Screening for chronic complications and vaccinations:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "prefix": 14.5,
                "text": "Hydroxycarbamide (hydroxyurea) should be stopped at least 3 months before conception. Angiotensin-converting  enzyme  inhibitors  and  angiotensin receptor blockers  should  be stopped before conception."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "prefix": 14.5,
                "text": "Patients with SCD should be prescribed Folic acid (5 mg) which should be given once daily both pre-conceptually and throughout pregnancy, due to the increased risk of folate deficiency."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "prefix": 14.7,
                "text": "Antenatal care should be provided by a multidisciplinary team including an obstetrician and a haematologist. Patients may require delivery in a specialist hospital. An antenatal anaesthetist appointment is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "prefix": 14.8,
                "text": "A neonatal alert form should be completed and sent to the Antenatal and Newborn Screening Co-ordinator, located in the Screening Office, Antenatal Clinic. A copy of the alert form is retained for the screening office records and a copy is forwarded to the named paediatric consultant for a plan of care post delivery (Refer to the \u2018Guideline for calling paediatric staff and for obtaining paediatric referral'; register number 09113)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "prefix": 14.9,
                "text": "When the named paediatric consultant has completed the neonatal alert form with a care plan, a copy will be retained in the neonatal folder. A further copy will be sent to the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "Antenatal and Newborn Screening Co-ordinator; who will then provide a subsequent copy for the Labour Ward folder. The Antenatal and Newborn Screening Co-ordinator will"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "provide a copy which should be filed in the patient's lilac folder."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Patients with SCD should aim to avoid precipitating factors of sickle cell crisis. The influenza vaccine should be recommended if it has not been administered in the previous year."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "prefix": 12.0,
                "text": "Patients with SCD should be considered for low-dose aspirin 75 mg once daily from  weeks of gestation in an effort to reduce the risk of developing pre-eclampsia."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "prefix": 14.12,
                "text": "Patients with SCD should be considered for prophylactic low-molecular-weight heparin during antenatal hospital admissions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "Patients should be offered the routine first-trimester scan (11\u201314 weeks of gestation) and a detailed anomaly scan at 20 weeks of gestation. In addition, women should be offered serial fetal biometry scans (growth scans) every 4 weeks from  weeks of gestation, as the baby is at risk of fetal growth restriction."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "prefix": 14.14,
                "text": "Patients with SCD should have an anaesthetic review in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "prefix": 14.15,
                "text": "Although Sickle Cell trait causes no problems in an uncomplicated pregnancy, it may be associated with the effects of intravascular sickling in periods of acute hypoxia or dehydration."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "prefix": 14.16,
                "text": "Iron status should be assessed and iron supplementation should be recommended only if there is evidence of iron deficiency."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "prefix": 14.17,
                "text": "Midstream urine for culture performed monthly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Sickle cell disease in labour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "Inform obstetric SHO (Senior House Officer), registrar or consultant on call, haemotologist and the anaesthetist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "prefix": 15.3,
                "text": "Blood to be obtained for full blood count (FBC) U&E, LFTS, and cross-match 4 units of blood."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "prefix": 15.4,
                "text": "Ensure good hydration and oxygenation during labour and postpartum to prevent sickle cell crisis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "prefix": 15.4,
                "text": "Send a mid-stream specimen of urine for culture and sensitivity."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "prefix": 15.5,
                "text": "Regional anaesthesia preferred. Epidural preferred to spinal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 0,
                "prefix": 15.6,
                "text": "Request cord blood, neonatal haemoglobinopathy screening of the newborn."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 0,
                "prefix": 15.7,
                "text": "Monitor for sickle cell crisis or infection."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "prefix": 14.8,
                "text": "Continuous monitoring of the fetal heart rate (FHR)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "prefix": 14.9,
                "text": "Prophylactic antibiotics for all anaesthetics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Do not use tourniquets ."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Indications for blood transfusion in sickle cell disease during pregnancy and the postpartum period"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 0,
                "prefix": 16.1,
                "text": "Depending on complications clinical indications and should be decided in the multidisciplinary clinic setting:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "text": "Top-up blood transfusion, if the haemoglobin is falling, and is less than 6.5 g/dl, but in severe hypoxia, and if the haemoglobin level is maintained, exchange transfusion will be required;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 0,
                "text": "Women who are on a transfusion regimen before pregnancy for primary or secondary stroke prevention or for the prevention of severe disease complications: Transfusion should be continued during pregnancy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "text": "Twin pregnancies: Prophylactic transfusion should be considered owing to the high rate of complications in these women;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "Acute anaemia: Top-up transfusion;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "text": "Acute chest syndrome or acute stroke: Exchange transfusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Management of sickle cell crisis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "prefix": 17.1,
                "text": "In the event of a sickle cell crisis the following should be adhered to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 0,
                "text": "Admit to the Consultant-led Maternity Unit without delay;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 0,
                "text": "Inform the Obstetric Registrar or Consultant on call, the Anaesthetist and the Consultant Haematologist on the patient's arrival;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 0,
                "text": "Assess the patient as soon as possible- look for precipitating factors;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 0,
                "text": "Initial analgesia should be given within 30 minutes of arriving at hospital and effective analgesia should be achieved within 1 hour. Avoid pethidine due to risk of toxicity and pethidine related seizures;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "Early recognition of ACS, characterised by respiratory symptoms such as tachypnoea, chest pain, cough and shortness of breath in the presence of a new infiltrate on the chest X-ray;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "Establish IV access, take blood for urgent FBC & reticulocytes, urea and electrolytes (U's & E's) and for HbS% (abnormal haemoglobin in sickle cell disease), group and save in case required;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "text": "Rehydrate with IV saline, unless the patient has an adequate oral intake (Fluid intake of at least 60ml/kg/24 hours) and maintain a fluid chart. Discuss with consultant if patient has h/o preeclampsia or PIH;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "text": "Monitor oxygen saturation levels (pO2) with pulse oxymetry and with arterial blood gases when indicated by symptoms and signs of anoxia as in chest infection and/or chest syndrome (sickling in the lungs);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "prefix": 15.0,
                "text": "Givelitres oxygen via reservoir mask. Aim >95%.oxygen saturations;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "text": "Referral to Intensive Care Team if haemodynamically unstable;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "text": "If paO2 < 11 kPa or paCO2 < 3.5/> 6 or respiratory rate <10/>30 consider transfer to HDU/ITU for continuous high pressure oxygen (CPAP) and urgent red cell exchange;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "Do not transfuse without discussion with a Haematology Consultant unless the haemoglobin (Hb) <60g/l or more than  - 30g/l below usual level;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 0,
                "text": "When symptoms or signs of infection present, send blood/sputum/urine for culture and request an urgent chest x-ray as appropriate;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "text": "Start oral/IV antibiotics when temperature > 38oc with amoxycillin or augmentin or cefuroxime. If temperature < 38oc carry on with penicillin V prophylaxis 500mg twice daily (bd);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 0,
                "text": "If crisis is severe admit under the care of the haematology team, preferably to the haematology ward. Do not transfer patient to another hospital without consulting the Haematology Consultant;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "text": "Thromboprophylaxis and TEDS should be given."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 1,
                "prefix": 17.2,
                "text": "Delivery and Postpartum Care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 0,
                "text": "17.2.1 Pregnant patients with SCD who have a normally growing fetus should be offered elective vaginal birth and induction of labour, or by elective caesarean section if indicated, after 38+0 weeks of gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 1,
                "text": "17.2.2 Continuous intrapartum electronic fetal heart rate monitoring is recommended owing to the increased risk of fetal distress which may necessitate operative delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 0,
                "text": "17.2.3 Cross match three units of blood for emergency use (Sickle cell disease patients frequently have red cell antibodies and are difficult to cross match)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 0,
                "text": "17.2.4 Ensure good hydration and oxygenation during labour and postpartum"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "text": "17.2.5 Epidural anaesthesia preferred"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 1,
                "prefix": 17.3,
                "text": "Postpartum management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 0,
                "text": "17.3.1 In pregnant women where the baby is at high risk of SCD (i.e. the partner is a carrier or affected), early testing for SCD should be offered. Capillary samples should be sent to laboratories where there is experience in the routine analysis of SCD in newborn samples. This will usually be at a regional centre."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 0,
                "text": "17.3.2 Maintain maternal oxygen saturation above 94% and adequate hydration based on fluid balance until discharge."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "text": "17.3.3 Low-molecular-weight heparin should be administered while in hospital and 7 days post- discharge following vaginal delivery or for a period of 6 weeks following caesarean section."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "text": "17.3.4 The same level of care and vigilance should be maintained as has been described for antenatal care, since acute crisis and other complications of SCD remain a risk in the puerperium."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "Acute chest syndrome"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 0,
                "prefix": 18.1,
                "text": "This is a rare but a life threatening complication."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 0,
                "prefix": 18.2,
                "text": "Symptoms:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 0,
                "text": "Chest pain;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 0,
                "text": "Cough;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 0,
                "text": "Wheeze;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 0,
                "text": "Haemoptysis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "prefix": 18.3,
                "text": "Signs:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 0,
                "text": "Pyrexia;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 0,
                "text": "decreased oxygen saturation;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 0,
                "text": "abnormal CXR- pulmonary infiltrates."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 0,
                "prefix": 18.4,
                "text": "Differential diagnosis:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 0,
                "text": "Acute chest syndrome;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 0,
                "text": "Pulmonary embolism;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 0,
                "text": "Chest infection."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 231,
            "data": {
                "is_heading": 0,
                "prefix": 18.5,
                "text": "Investigation:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 232,
            "data": {
                "is_heading": 0,
                "text": "Obtain a blood sample for FBC, U's & E's, CRP, ESR;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 233,
            "data": {
                "is_heading": 0,
                "text": "Arterial blood gas;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 0,
                "text": "CXR (chest x-ray) ;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 235,
            "data": {
                "is_heading": 0,
                "text": "Spiral CT (better than V/Q if PE suspected as chest syndrome can give perfusion defects)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 236,
            "data": {
                "is_heading": 0,
                "prefix": 18.6,
                "text": "Management:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 237,
            "data": {
                "is_heading": 0,
                "text": "Analgesia;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 0,
                "text": "Oxygenation;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 239,
            "data": {
                "is_heading": 0,
                "text": "Antibiotics if signs/symptoms of infection;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 240,
            "data": {
                "is_heading": 0,
                "text": "Transfusion / exchange transfusion;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 0,
                "text": "Consider use of thromboprophylaxis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 242,
            "data": {
                "is_heading": 1,
                "text": "Must involve the Haematologist and Consultant Obstetrician input from the outset."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 243,
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Management of thalassaemia in pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 244,
            "data": {
                "is_heading": 0,
                "prefix": 19.1,
                "text": "Thalassaemia major (homozygous \u03b2 thalassaemia) results from the inheritance of a defective \u03b2 globin gene from each parent. This results in a severe transfusion-dependent anaemia. The heterozygous state, \u03b2 thalassaemia trait (thalassaemia minor) causes mild to moderate microcytic anaemia with no significant detrimental effect on overall health. Thalassaemia intermedia is defined as a group of patients with \u03b2 thalassaemia whose disease severity varies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 245,
            "data": {
                "is_heading": 0,
                "prefix": 19.2,
                "text": "The cornerstones of modern treatment in \u03b2 thalassaemia are blood transfusion and iron chelation therapy. Multiple transfusions cause iron overload resulting in hepatic, cardiac and endocrine dysfunction. Cardiac failure is the primary cause of death in over 50% of cases."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 246,
            "data": {
                "is_heading": 0,
                "prefix": 19.3,
                "text": "The absolute number of affected individuals is unclear and is currently being assessed nationally as part of the National Haemoglobinopathy Registry. Previously, the community affected was principally from Cyprus and the Mediterranean. However, currently the Asian communities of India, Pakistan and Bangladesh account for 79% of thalassaemia births with only 7% occurring in the Cypriot population who have taken advantage of the availability of prenatal diagnosis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 247,
            "data": {
                "is_heading": 0,
                "prefix": 19.4,
                "text": "\u03b2 thalassaemia trait. Patients with this condition are often anaemic. Folic acid 5mg/day,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 248,
            "data": {
                "is_heading": 0,
                "text": "should be given and oral iron supplementation only if the ferritin level is low. If a patient"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 249,
            "data": {
                "is_heading": 0,
                "text": "had normal ferritin levels and symptoms of anaemia, in some cases the patients may need a blood transfusion. Women who are thalassaemia carriers generally do not require"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 250,
            "data": {
                "is_heading": 0,
                "text": "transfusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 251,
            "data": {
                "is_heading": 0,
                "prefix": 19.5,
                "text": "Haemolytic Anaemia (HbH disease). These patients often have a chronic haemolytic"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 252,
            "data": {
                "is_heading": 0,
                "text": "anaemia and require folic acid 5 mg/day. They are not often iron deficient and transfusions may be offered to correct the anaemia."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 253,
            "data": {
                "is_heading": 0,
                "prefix": 19.6,
                "text": "Haemoglobin Barts (HbBarts - related to alpha thalassaemia major).This condition is compatible with life, from a fetal perspective, however, maternal problems during the pregnancy can include severe early onset pre-eclampsia, delivery difficulties with a grossly hydropic fetus and postpartum haemorrhage."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 254,
            "data": {
                "is_heading": 1,
                "prefix": 19.7,
                "text": "Preconception Counselling"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 255,
            "data": {
                "is_heading": 0,
                "text": "19.7.1 Optimise general health."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 256,
            "data": {
                "is_heading": 0,
                "text": "19.7.2 Screen for Diabetes and Thyroid dysfunction."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 257,
            "data": {
                "is_heading": 0,
                "text": "19.7.3 Liaise with Haemophilia centre."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 258,
            "data": {
                "is_heading": 0,
                "text": "19.7.4 Aggressive chelation in the preconception stage can reduce and optimise body iron burden and reduce end-organ damage."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 259,
            "data": {
                "is_heading": 0,
                "text": "19.7.5 ECHO to exclude cardiomyopathy in patients with known history of iron overload."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 260,
            "data": {
                "is_heading": 0,
                "text": "19.7.6 Iron chelators should be reviewed and deferasirox and deferiprone ideally discontinued 3 months before conception. Desferrioxamine is the only chelation agent with a body of evidence for use in the second and third trimester. The optimisation of iron burden is therefore critical as the ongoing iron accumulation from transfusion in the absence of chelation may expose the pregnant woman to a high risk of new complications related to iron overload, particularly diabetes and cardiomyopathy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 261,
            "data": {
                "is_heading": 0,
                "text": "19.7.7 Women with established diabetes mellitus should ideally have serum fructosamine concentrations < 300 nmol/l for at least 3 months prior to conception. This is equivalent to an HbA1c of 43 mmol/mol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 262,
            "data": {
                "is_heading": 0,
                "text": "19.7.8 Women should be assessed for liver iron concentration using a FerriScan\u00ae. Ideally the liver iron should be < 7 mg/g (dry weight). Liver and gall bladder (and spleen if present) ultrasound should be used to detect cholethiasis and evidence of liver cirrhosis due to iron overload or transfusion-related viral hepatitis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 263,
            "data": {
                "is_heading": 0,
                "text": "19.7.9 Serum vitamin D concentrations should be optimised."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 264,
            "data": {
                "is_heading": 0,
                "text": "19.7.10 Vaccinations up to date."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 265,
            "data": {
                "is_heading": 0,
                "text": "19.7.11 Check  Hepatitis B and C status."
            }
        },
        {
            "type": "image",
            "sequence_num": 266,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 267,
            "data": {
                "is_heading": 0,
                "text": "19.7.12 Folic acid 5 mg daily should be commenced 3 months prior to conception"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 268,
            "data": {
                "is_heading": 1,
                "prefix": 19.8,
                "text": "Antenatal Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 269,
            "data": {
                "is_heading": 0,
                "text": "19.8.1 Women with thalassaemia should be reviewed monthly until 28 weeks of gestation and fortnightly thereafter."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 270,
            "data": {
                "is_heading": 0,
                "text": "19.8.2 The multidisciplinary team should provide routine as well as specialist antenatal care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 271,
            "data": {
                "is_heading": 0,
                "text": "19.8.3 Women with both thalassaemia and diabetes should have monthly assessment of serum fructosamine concentrations and review in the specialist diabetic pregnancy clinic."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 272,
            "data": {
                "is_heading": 0,
                "text": "19.8.4 All women with thalassaemia major should undergo specialist cardiac assessment at 28 weeks of gestation and thereafter as appropriate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 273,
            "data": {
                "is_heading": 0,
                "text": "19.8.5 Thyroid function should be monitored during pregnancy in hypothyroid patients."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 274,
            "data": {
                "is_heading": 0,
                "text": "19.8.6 Women should be offered an early scan at 7\u20139 weeks of gestation. Women should be offered serial fetal biometry scans every 4 weeks from 24weeks of gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 275,
            "data": {
                "is_heading": 1,
                "prefix": 19.9,
                "text": "Guidance on Blood transfusion"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 276,
            "data": {
                "is_heading": 0,
                "text": "19.9.1 All women with thalassaemia major should be receiving blood transfusions on a regular basis aiming for a pretransfusion haemoglobin of 100 g/l."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 277,
            "data": {
                "is_heading": 0,
                "prefix": 100.0,
                "text": "19.9.2 The decision to initiate a transfusion regimen is a clinical one based on the woman's symptoms and fetal growth. If there is worsening maternal anaemia or evidence of FGR, regular transfusions should be started aiming for maintenance of pre-transfusion haemoglobin concentration above  g/l. Initially a 2\u20133 unit transfusion should be administered with additional top-up transfusion if necessary the following week until the haemoglobin reaches 120 g/l."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 278,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "19.9.3 The haemoglobin should be monitored after  to  weeks and a 2-unit transfusion administered if the haemoglobin has fallen below 100 g/l. Each woman's haemoglobin falls at different rates after transfusion so close surveillance of pre-transfusion haemoglobin concentrations is required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 279,
            "data": {
                "is_heading": 0,
                "text": "19.9.4 In non-transfused patients, if the haemoglobin is above 80 g/l at 36 weeks of gestation, transfusion can be avoided prior to delivery. Postnatal transfusion can be provided as necessary."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 280,
            "data": {
                "is_heading": 0,
                "text": "19.9.5 If the haemoglobin is less than 80 g/l then aim for a top-up transfusion of 2 units at 37\u201338 weeks of gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 281,
            "data": {
                "is_heading": 1,
                "prefix": 19.1,
                "text": "Guidance on antenatal thromboprophylaxis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 282,
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "19.10.1. Women with thalassaemia who have undergone splenectomy or have a platelet count greater than  x  /L should commence or continue taking low-dose aspirin (75 mg/day)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 283,
            "data": {
                "is_heading": 0,
                "text": "19.10.2. Women who have undergone splenectomy and have a platelet count above"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 284,
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "600 x /L should be offered low-molecular-weight heparin thromboprophylaxis as well as low-dose aspirin (75 mg/day)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 285,
            "data": {
                "is_heading": 0,
                "text": "19.10.3 Women with thalassaemia who are not already using prophylactic low-molecular-weight heparin should be advised to use it during antenatal hospital admissions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 286,
            "data": {
                "is_heading": 1,
                "prefix": 19.11,
                "text": "Guidance on iron chelation therapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 287,
            "data": {
                "is_heading": 0,
                "text": "19.11.1Iron chelation therapy is complex and should be tailored to the needs of the individual"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 288,
            "data": {
                "is_heading": 0,
                "text": "woman."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 289,
            "data": {
                "is_heading": 0,
                "text": "19.11.2 The chelation should be managed by a haematologist with experience in iron chelation therapy particularly during pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 290,
            "data": {
                "is_heading": 1,
                "prefix": 19.12,
                "text": "Management of women with myocardial iron (Cardiomyopathy secondary to Fe Overload)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 291,
            "data": {
                "is_heading": 0,
                "text": "19.12.1 Women with myocardial iron loading should undergo regular cardiology review with careful monitoring of ejection fraction during the pregnancy as signs of cardiac decompensation are the primary indications for intervention with chelation therapy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 292,
            "data": {
                "is_heading": 0,
                "text": "19.12.2 Those women at highest risk of cardiac decompensation should commence low-dose subcutaneous desferrioxamine (20 mg/kg/day) on a minimum of 4\u20135 days a week under joint haematology and cardiology guidance from 20\u201324 weeks of gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 293,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "19.12.3 Women with severe hepatic iron loading should be carefully reviewed and consideration given to low dose desferrioxamine iron chelation from  weeks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 294,
            "data": {
                "is_heading": 1,
                "prefix": 19.13,
                "text": "Intrapartum care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 295,
            "data": {
                "is_heading": 0,
                "text": "19.13.1 There is no specific evidence regarding the timing or mode of delivery for women with thalassaemia. Timing of delivery should be in line with national guidance for any related complications (e.g. diabetes or FGR)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 296,
            "data": {
                "is_heading": 0,
                "text": "19.13.2 Senior midwifery, obstetric, anaesthetic and haematology staff should be informed as soon as the woman is admitted to the delivery suite."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 297,
            "data": {
                "is_heading": 0,
                "text": "19.13.3 In the presence of red cell antibodies, blood should be cross-matched for delivery since this may delay the availability of blood. Otherwise a group and save will suffice. If haemoglobin is less than 100 g/l, cross-match 2 units on admission."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 298,
            "data": {
                "is_heading": 0,
                "text": "19.13.4 In women with thalassaemia major intravenous desferrioxamine 2 g over 24 hours should be administered for the duration of labour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 299,
            "data": {
                "is_heading": 0,
                "text": "19.13.5 Continuous intrapartum electronic fetal monitoring."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 300,
            "data": {
                "is_heading": 0,
                "text": "19.13.6 Thalassaemia in itself is not an indication for caesarean section."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 301,
            "data": {
                "is_heading": 0,
                "text": "19.13.7 Active management of the third stage of labour is recommended to minimise blood loss."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 302,
            "data": {
                "is_heading": 1,
                "prefix": 19.14,
                "text": "Postpartum management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 303,
            "data": {
                "is_heading": 0,
                "text": "19.14.1 Low-molecular-weight heparin should be administered for 7 days post discharge following vaginal delivery or for 6 weeks following caesarean section."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 304,
            "data": {
                "is_heading": 0,
                "text": "19.14.2 Women with thalassaemia major who plan to breastfeed should restart desferrioxamine as soon as the initial 24-hour infusion of intravenous desferrioxamine finishes after delivery. Desferrioxamine is secreted in breast milk but is not orally absorbed and therefore not harmful to the newborn."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 305,
            "data": {
                "is_heading": 0,
                "text": "19.14.3 If a woman decides not to breastfeed, intravenous or subcutaneous desferrioxamine infusions are continued until discharge from hospital or until resumption of her previous iron chelation regimen under haematology supervision, whichever is sooner."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 306,
            "data": {
                "is_heading": 1,
                "prefix": 20.0,
                "text": "Staff and training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 307,
            "data": {
                "is_heading": 0,
                "prefix": 20.1,
                "text": "Only qualified medical staff with experience in haematological disorders should be involved in the initial management plan of the patient. They can seek junior medical or midwifery assistance depending on their experience."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 308,
            "data": {
                "is_heading": 0,
                "prefix": 20.2,
                "text": "All qualified midwifery and obstetric staff who have undertaken the National Patient Safety Agency (NPSA) competency Level 1 in taking samples for blood transfusion purposes are deemed fully trained to take maternal blood."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 309,
            "data": {
                "is_heading": 0,
                "prefix": 20.3,
                "text": "Some Maternal Care Assistants (MCA's) are also trained to perform maternal venepuncture, in line with the training outlined by the NPSA (refer to point16.2). Regular updates for venepuncture are available from the Practice Development Midwife. Midwifery students may undertake venepuncture once they have received the theoretical knowledge and while under supervision of a midwife or obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 310,
            "data": {
                "is_heading": 1,
                "prefix": 20.3,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 311,
            "data": {
                "is_heading": 0,
                "text": "20.3.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 312,
            "data": {
                "is_heading": 1,
                "prefix": 21.0,
                "text": "Infection prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 313,
            "data": {
                "is_heading": 0,
                "prefix": 21.1,
                "text": "All staff should follow Trust guidelines on infection prevention by ensuring that they effectively \u2018decontaminate their hands' before and after each procedure and when taking bloods samples to use the Aseptic Non -Touch Technique (ANTT)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 314,
            "data": {
                "is_heading": 0,
                "prefix": 21.2,
                "text": "All staff should ensure that they follow Trust guidelines on infection prevention. All invasive devices must be inserted and cared for using High Impact Intervention guidelines to reduce the risk of infection and deliver safe care. This care should be recorded in the Saving Lives High Impact Intervention Monitoring Tool Paperwork (Medical Devices)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 315,
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "Audit and monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 316,
            "data": {
                "is_heading": 0,
                "prefix": 22.1,
                "text": "Audit of compliance with this guideline will be considered on an annual audit basis in accordance with the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity annual audit work plan; to encompass national and local audit and clinical governance identifying"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 317,
            "data": {
                "is_heading": 0,
                "text": "key harm themes. The Women's and Children's Clinical Audit Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 318,
            "data": {
                "is_heading": 0,
                "text": "As a minimum the following specific requirements will be monitored:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 319,
            "data": {
                "is_heading": 0,
                "text": "Designated lead for Antenatal Newborn Screening Co-ordinator in the maternity Services"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 320,
            "data": {
                "is_heading": 0,
                "text": "Antenatal screening tests, which follow the UK National Screening Committee guidance"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 321,
            "data": {
                "is_heading": 0,
                "text": "System for ensuring that appropriate tests are undertaken within appropriate timescales"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 322,
            "data": {
                "is_heading": 0,
                "text": "System for ensuring that appropriate tests are undertaken when patients book late"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 323,
            "data": {
                "is_heading": 0,
                "text": "Process for the review of the results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 324,
            "data": {
                "is_heading": 0,
                "text": "Process for reporting all results to patients"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 325,
            "data": {
                "is_heading": 0,
                "text": "Process for reporting results to other relevant healthcare professionals"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 326,
            "data": {
                "is_heading": 0,
                "text": "Process for ensuring that women with screen positive test results are referred and managed within appropriate timescales"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 327,
            "data": {
                "is_heading": 0,
                "text": "Maternity service's expectations for staff training, as identified in the training needs analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 328,
            "data": {
                "is_heading": 0,
                "text": "Process for audit, multidisciplinary review of results and subsequent monitoring of action plans"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 329,
            "data": {
                "is_heading": 0,
                "prefix": 22.2,
                "text": "A review of a suitable sample will be audited from the health care records of patients who have delivered process for the review of the results to evidence the process for ensuring that patients with screen positive test results are referred and managed within appropriate timescales. A minimum compliance 75% is required for each requirement. Where concerns are identified more frequent audit will be undertaken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 330,
            "data": {
                "is_heading": 0,
                "prefix": 22.3,
                "text": "The findings of the audit will be reported to and approved by the Multi-disciplinary Risk Management Group (MRMG) and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 331,
            "data": {
                "is_heading": 0,
                "prefix": 22.4,
                "text": "The audit report will be reported to the monthly Directorate Governance Meeting (DGM) and significant concerns relating to compliance will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 332,
            "data": {
                "is_heading": 0,
                "prefix": 22.5,
                "text": "Key findings and learning points from the audit will be submitted to the Clinical Governance Group within the integrated learning report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 333,
            "data": {
                "is_heading": 0,
                "prefix": 22.6,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 334,
            "data": {
                "is_heading": 1,
                "prefix": 23.0,
                "text": "Approval and Implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 335,
            "data": {
                "is_heading": 0,
                "prefix": 23.1,
                "text": "All policies, procedures and guidelines will be approved locally by the Maternity and Gynaecology Practice Steering Group prior to submission to the Controlled Document team for ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 336,
            "data": {
                "is_heading": 0,
                "prefix": 23.2,
                "text": "It is the Guidelines and Audit Nurse's and author's responsibility to inform the Maternity and Gynaecology Practice Steering Group and appropriate Maternity Services' staff of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 337,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 338,
            "data": {
                "is_heading": 0,
                "text": "Public Health England (2019). Sickle cell and thalassaemia screening programme: standards. London:PHE. Available at: www.gov.uk/government/publications/sickle-cell-and- thalassaemia-screening-programme-standards"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 339,
            "data": {
                "is_heading": 0,
                "text": "Public Health England (2017). NHS Sickle cell and thalassaemia screening programme, Handbook for laboratories. London:PHE. Available at: www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-handbook- for-laboratories"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 340,
            "data": {
                "is_heading": 0,
                "text": "Royal College of Obstetricians and Gynaecologists (2011) Management of sickle cell disease in pregnancy (Green top guideline No 61). London:RCOG. Available at: www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg61"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 341,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobinopathy screening in pregnancy/08041/7.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 342,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 343,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobinopathy screening in pregnancy/08041/7.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 344,
            "data": {
                "is_heading": 1,
                "text": "Appendix A: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 345,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Haemoglobinopathy screening in pregnancy/08041"
            }
        },
        {
            "type": "table",
            "sequence_num": 346,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2612 A change to an existing policy"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2610 A new policy"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 347,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Review of NHS Sickle Cell and Thalassaemia Screening Programme Standards 2017"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Full 3 year review"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and Clinicians"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to Pages 1 and 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 348,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Emma Neate"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Antenatal and Newborn Screening Co-ordinator"
                    },
                    {
                        "text": "30 June 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 349,
            "data": {
                "is_heading": 0,
                "prefix": 28.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 350,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobinopathy screening in pregnancy/08041/7.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 351,
            "data": {
                "is_heading": 1,
                "text": "Appendix B: Letter to woman regarding Sickle Cell and Thalassaemia screening in pregnancy results"
            }
        },
        {
            "type": "image",
            "sequence_num": 352,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 353,
            "data": {
                "is_heading": 1,
                "text": "Broomfield Hospital Court Road Chelmsford"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 354,
            "data": {
                "is_heading": 0,
                "text": "Essex CM1 7ET"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 355,
            "data": {
                "is_heading": 0,
                "text": "Tel. 01245 513433"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 356,
            "data": {
                "is_heading": 0,
                "text": "Dear"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 357,
            "data": {
                "is_heading": 0,
                "text": "I am writing to inform you that the results of your Sickle Cell and Thalassaemia screening in pregnancy, has identified you as a carrier for Sickle Cell / Thalassaemia \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 358,
            "data": {
                "is_heading": 0,
                "text": "Following a discussion around the implications of these results for your pregnancy; we arranged father of the baby screening, these results have identified that the father of the baby is not a carrier for either of the conditions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 359,
            "data": {
                "is_heading": 0,
                "text": "This means that the combination of your result and the father of the baby's results do not put the baby at any risk of Sickle Cell / Thalassaemia."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 360,
            "data": {
                "is_heading": 0,
                "text": "There is no need for you to have any additional care in pregnancy and the baby will have screening in the postnatal period, as part of the Newborn Bloodspot screening to identify if they carry the Sickle Cell / Thalassaemia gene."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 361,
            "data": {
                "is_heading": 0,
                "text": "Please keep this letter safe and give it to the Midwife / Maternity Care Assistant when they do the screening so that the results can be added to the card to aid screening of the baby."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 362,
            "data": {
                "is_heading": 0,
                "text": "If you require any further information please contact the Screening Midwife on the above telephone number."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 363,
            "data": {
                "is_heading": 0,
                "text": "Yours truly"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 364,
            "data": {
                "is_heading": 0,
                "text": "Antenatal & Newborn Screening Team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 365,
            "data": {
                "is_heading": 0,
                "text": "Copy to Woman / Midwife team / G"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 366,
            "data": {
                "is_heading": 0,
                "prefix": 29.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 367,
            "data": {
                "is_heading": 0,
                "text": "Haemoglobinopathy screening in pregnancy/08041/6.05(2)draft"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 368,
            "data": {
                "is_heading": 1,
                "text": "Appendix C: Haemoglobinopathy Alert Form"
            }
        },
        {
            "type": "image",
            "sequence_num": 369,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.006.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 370,
            "data": {
                "is_heading": 1,
                "prefix": 31.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 371,
            "data": {
                "is_heading": 1,
                "text": "Appendix D  Haemoglobinopathy screening in pregnancy/08041/6.05(2)draft"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 372,
            "data": {
                "is_heading": 1,
                "text": "Antenatal and Newborn Screening \u2013 Haemoglobinopathy Screening Standard Operating Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 373,
            "data": {
                "is_heading": 1,
                "text": "Women refer for Antenatal Care"
            }
        },
        {
            "type": "image",
            "sequence_num": 374,
            "data": {
                "url": "08041 Haemoglobinopathy Screening in Pregnancy 7.0.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 375,
            "data": {
                "is_heading": 1,
                "text": "Referral processed and initial booking appointment arranged to see Midwife \u2013 letter sent to women with information regarding their booking appointment, scan date"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 376,
            "data": {
                "is_heading": 1,
                "text": "Antenatal Booking Performed ideally before 10 weeks, screening discussed and screening offered for Haemoglobinopathy Screening. Screening tests for you and your baby booklet given"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 377,
            "data": {
                "is_heading": 1,
                "text": "Screening Negative Results  Miscarried /  Screening Positive Results Termination of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 378,
            "data": {
                "is_heading": 1,
                "text": "pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 379,
            "data": {
                "is_heading": 1,
                "text": "Results reviewed by Community  Copy of blood result is sent via Midwife, results given to woman  Letter sent  the generic screening email"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 380,
            "data": {
                "is_heading": 1,
                "text": "at 16 week check  Letter sent  to woman  address to screening office by to woman  to contact  laboratory staff with request for"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 381,
            "data": {
                "is_heading": 1,
                "text": "to inform of  screening  Father of the baby screening negative  team  (FOB)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 382,
            "data": {
                "is_heading": 1,
                "text": "result by"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 383,
            "data": {
                "is_heading": 1,
                "text": "screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 384,
            "data": {
                "is_heading": 1,
                "text": "team  Woman contacted and informed of results, arranged to see to discuss"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 385,
            "data": {
                "is_heading": 1,
                "text": "results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 386,
            "data": {
                "is_heading": 1,
                "text": "Seen/ or discussed via phone. Counselled by Screening Midwives \u2013Information Leaflet given appropriate to result, offered Father of the baby screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 387,
            "data": {
                "is_heading": 1,
                "text": "FOB screening arranged, discussed screening with FOB, give PHE leaflet, bloods taken and sent to the laboratory"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 388,
            "data": {
                "is_heading": 1,
                "text": "Screening team review FOB results three days after screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 389,
            "data": {
                "is_heading": 1,
                "text": "No further action  Results \u2013 Negative  Results \u2013 carrier status"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 390,
            "data": {
                "is_heading": 1,
                "text": "Inform woman of FOB results, possible outcome for babies Haemoglobinopathy status based on maternal and paternal results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 391,
            "data": {
                "is_heading": 1,
                "text": "Results \u2013 if maternal and paternal screening makes baby high risk for condition, discuss prenatal testing for baby's status"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 392,
            "data": {
                "is_heading": 1,
                "text": "If diagnostic testing accepted  Neonatal Consultant aware of results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 393,
            "data": {
                "is_heading": 1,
                "text": "contact UCLH to arrange testing  \u2013 plan of care made for post-delivery  If diagnostic testing declined"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 394,
            "data": {
                "is_heading": 1,
                "text": "care / treatment \u2013 Neonatal Alert"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 395,
            "data": {
                "is_heading": 1,
                "text": "Completed"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 396,
            "data": {
                "is_heading": 1,
                "text": "Await results \u2013 can take two"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 397,
            "data": {
                "is_heading": 1,
                "text": "Continuing with  Alert form to Sickle Cell Negative result  Positive result  pregnancy  team by the Screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 398,
            "data": {
                "is_heading": 1,
                "text": "Team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 399,
            "data": {
                "is_heading": 1,
                "prefix": 31.0,
                "text": "Inform parents \u2013  Inform parents \u2013  Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 400,
            "data": {
                "is_heading": 1,
                "text": "no further action  discuss next steps  Termination of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 401,
            "data": {
                "is_heading": 1,
                "text": "Pregnancy"
            }
        }
    ]
}